PMID- 33549009
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 10
IP  - 3
DP  - 2021 Mar
TI  - The impact of metabolic syndrome on the safety and efficacy of flexible 
      ureterorenoscopy.
PG  - 2776-2780
LID - 10.21037/apm-20-2143 [doi]
AB  - BACKGROUND: To analyze the impact of metabolic syndrome on the safety and 
      efficacy of flexible ureterorenoscopy (fURS) in managing kidney calculi. METHODS: 
      We retrospectively analyzed the records of 151 patients who received fURS for the 
      renal stones in our center between January 2014 and December 2016. The patients 
      were divided into two groups based on whether they were diagnosed with metabolic 
      syndrome. Information related to the patients, stones and surgeries were 
      analyzed, and the stone-free rates (SFRs) and complications after fURS were 
      reviewed. RESULTS: Group 1 consisted of patients with metabolic syndrome, and 
      group 2 contained patients without metabolic syndrome. The mean stone size was 
      71.9+/-58.3 mm2 in group 1 and 64.9+/-43.7 mm2 in group 2 (P=0.399). The mean 
      hospitalization and surgical durations were similar between both groups (P>0.05). 
      The overall complication rates were 8.3% vs. 12.1% (P=0.514). The SFR at 3 months 
      postoperative in group 1 was significantly lower than that in group 2 (80% vs. 
      92.3%, P<0.05). CONCLUSIONS: Our study results revealed that patients with 
      metabolic syndrome can be treated safely with fURS. however, metabolic syndrome 
      has a negative impact on the efficacy of fURS in the treatment of patients with 
      kidney stone.
FAU - Liu, Jun
AU  - Liu J
AD  - Urology and lithotripsy center, Peking University People's Hospital, Beijing, 
      China; Peking University applied lithotripsy institute, Beijing, China.
FAU - Hong, Yang
AU  - Hong Y
AD  - Urology and lithotripsy center, Peking University People's Hospital, Beijing, 
      China; Peking University applied lithotripsy institute, Beijing, China.
FAU - Yang, Bo
AU  - Yang B
AD  - Urology and lithotripsy center, Peking University People's Hospital, Beijing, 
      China; Peking University applied lithotripsy institute, Beijing, China. 
      huang6299@sina.com.
FAU - Huang, Xiaobo
AU  - Huang X
AD  - Urology and lithotripsy center, Peking University People's Hospital, Beijing, 
      China; Peking University applied lithotripsy institute, Beijing, China.
FAU - Xu, Qingquan
AU  - Xu Q
AD  - Urology and lithotripsy center, Peking University People's Hospital, Beijing, 
      China; Peking University applied lithotripsy institute, Beijing, China.
FAU - Xiong, Liulin
AU  - Xiong L
AD  - Urology and lithotripsy center, Peking University People's Hospital, Beijing, 
      China; Peking University applied lithotripsy institute, Beijing, China.
FAU - Wang, Xiaofeng
AU  - Wang X
AD  - Department of Urology, Peking University International Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210128
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
SB  - IM
MH  - Humans
MH  - *Kidney Calculi/surgery
MH  - *Metabolic Syndrome
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Ureteroscopy
OTO - NOTNLM
OT  - Flexible ureterorenoscopy (fURS)
OT  - kidney stone
OT  - metabolic syndrome
OT  - stone-free rates (SFRs)
EDAT- 2021/02/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/02/07 20:25
PHST- 2020/10/30 00:00 [received]
PHST- 2020/12/08 00:00 [accepted]
PHST- 2021/02/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/02/07 20:25 [entrez]
AID - apm-20-2143 [pii]
AID - 10.21037/apm-20-2143 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2021 Mar;10(3):2776-2780. doi: 10.21037/apm-20-2143. Epub 2021 
      Jan 28.